Drug
Tegobuvir clinical trials
Also written GS-9190.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses tegobuvir is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CCompletedPhase 2Gilead SciencesNCT01271790Written as Tegobuvir (GS-9190)
- A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CCompletedPhase 2Gilead SciencesNCT01225380Written as GS-9190
- GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) InfectionCompletedPhase 2Gilead SciencesNCT01353248Written as Tegobuvir
- GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) InfectionCompletedPhase 2Gilead SciencesNCT01434498Written as tegobuvir capsule
- GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) InfectionCompletedPhase 2Gilead SciencesNCT01435226Written as tegobuvir
- Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV InfectionCompletedPhase 2Gilead SciencesNCT00743795Written as GS-9190
Given in every arm · 1 — tegobuvir is usual care beside what is tested
Codes
What other systems call tegobuvir · ClinicalTrials.gg INT006054
- MeSH (NLM) C571890tegobuvirOne source NLM
- UNII (FDA) 5NOK5X389MTEGOBUVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q27262603tegobuvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152541TegobuvirOne source FDA
- DrugBank DB11852One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571890 | tegobuvir | One source NLM |
| UNII (FDA) | 5NOK5X389M | TEGOBUVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27262603 | tegobuvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152541 | Tegobuvir | One source FDA |
| DrugBank | DB11852 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.